Will taking venetoclax lead to an increase in the number of blasts?

Taking venetoclax does not result in an increase in the number of blasts. In fact, its function is to induce abnormal cell apoptosis by inhibiting the expression of BCL-2 protein, thereby reducing the number of abnormal cells.

Venetoclax is a small molecule drug targeting BCL-2. Its main function is to kill tumor cells by inducing the endogenous apoptosis pathway. In clinical trials and practical applications, venetoclax has demonstrated significant therapeutic effects on certain types of leukemia.

Regarding primitive cells, these are immature cells in the blood that normally mature and perform their functions. But in some diseases, such as leukemia, there is an abnormal increase in blast cells. However, venetoclax works precisely on these abnormal cells, reducing their numbers through its own unique mechanism.

Venetoclax promotes the normal death of cancer cells by selectively binding toBCL-2 protein. This process is achieved by inducing the intrinsic apoptosis pathway, which activates the apoptotic program inside the cell, leading to the self-destruction of abnormal cells.

Since the goal of venetoclax is to induce apoptosis in abnormal cells, it actually reduces the number of blast cells (in the case of abnormal, blast cells with the capacity for malignant proliferation) rather than increasing them. This has been verified in clinical trials and practical applications.

Venetoclax is already approved to treat certain types of leukemia, especially when combined with drugs such as azacitidine, providing a new treatment option for patients who are not candidates for strong induction chemotherapy. Its efficacy has been confirmed in multiple clinical trials.